These data are consistent with two previous reports indicating that another mineralocorticoid receptor inhibitor, eplerenone, and aldosterone synthase inhibitors are effective at slowing plaque growth in a mouse ApoE−/− model of aortic atherosclerosis [20, 31] and a recent initial clinical study reporting that spironolactone may decrease atherosclerosis in humans [37]. Here, NR3C2 is linked to aortic atherosclerosis.